<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089062</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0004-CL-P102</org_study_id>
    <nct_id>NCT01089062</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of Intravenous Dihydroergotamine (DHE) and Orally Inhaled DHE (MAP0004) on Pulmonary Arterial Pressure and Tolerability in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the acute effects and tolerability of Dihydroergotamine Mesylate (DHE) delivered by
      Oral Inhalation (MAP0004) versus by intravenous (IV) infusion in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose</measure>
    <time_frame>2 hours from time of first dose</time_frame>
    <description>AUC(0-2hrs) (Area Under the Curve, time 0-2 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With an Increase in PASP Greater Than 10mmHg From Baseline to 2 Hours From the First Dose</measure>
    <time_frame>baseline and 2 hours from the time of first dose</time_frame>
    <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change in PASP From Baseline to the Two Hour Period Following the First Dose</measure>
    <time_frame>baseline and 2 hours from the time of first dose</time_frame>
    <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-4hrs) of Pulmonary Arterial Systolic Pressure (PASP) From the Start of the First Dose to Two Hours After the Second Dose</measure>
    <time_frame>4 hours from the time of first dose</time_frame>
    <description>AUC(0-4hrs) (Area Under the Curve, time 0-4 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure From Baseline After the Two 2-hour Post Dosing Periods</measure>
    <time_frame>baseline, 10 minutes post 1st dose, 10 minutes post 2nd dose</time_frame>
    <description>Systolic and diastolic blood pressure measure the lowest and highest pressures against the walls of the arteries. Changes were calculated from 30 minutes pre dose (baseline) to 10 minutes post first and second dose. A positive change from baseline indicates an increase in blood pressure and a negative change indicates a decrease in blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTc Interval at 14 Minutes After the 1st and 2nd Dose</measure>
    <time_frame>baseline, 14 minutes from time of 1st dose, 14 minutes from time of 2nd dose</time_frame>
    <description>The corrected QT interval (QTc) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0004</intervention_name>
    <description>1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Placebo (Saline)</intervention_name>
    <description>IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Inhaler</intervention_name>
    <description>Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Dihydroergotamine Mesylate (DHE)</intervention_name>
    <description>IV DHE administered in Treatment A as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
    <other_name>D.H.E.45®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide a signed, executed written informed consent

          2. Healthy non-smoking adult volunteers: Male or Female subjects 18 to 45 years old

          3. Female subjects who are practicing adequate contraception

          4. Stable cardiac status

          5. Normal hemoglobin values

          6. Normal Echocardiogram

          7. Normal or not clinically significant 12-lead Electrocardiogram

          8. Demonstrated ability to properly use the Tempo® Inhaler

          9. Subject has not donated blood in the last 56 days

        Exclusion Criteria:

          1. Contraindication to dihydroergotamine mesylate (DHE)

          2. Use of any excluded concomitant medications within the 10 days prior to Visit 1

          3. History of hemiplegic or basilar migraine

          4. Participation in another investigational trial during the 30 days prior to Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Noveck, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroergotamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a 3-treatment, 3-period, 6-sequence crossover study. Each subject received all 3 treatments in a randomly assigned order: treatments A, B, and C, the sequences were ABC, ACB, BAC, BCA, CAB, and CBA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A, Then B, Then C</title>
          <description>The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment A = inhaler placebo and Intravenous (IV) Dihydroergotamine (DHE) for first dose, inhaler placebo for second dose at Visit 2.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4.</description>
        </group>
        <group group_id="P2">
          <title>Treatment A, Then C, Then B</title>
          <description>The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4.</description>
        </group>
        <group group_id="P3">
          <title>Treatment B, Then A, Then C</title>
          <description>The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4.</description>
        </group>
        <group group_id="P4">
          <title>Treatment B, Then C, Then A</title>
          <description>The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4.</description>
        </group>
        <group group_id="P5">
          <title>Treatment C, Then A, Then B</title>
          <description>The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4.</description>
        </group>
        <group group_id="P6">
          <title>Treatment C, Then B, Then A</title>
          <description>The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 2 (Randomization)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Visit (Final Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment A, Then B, Then C</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B2">
          <title>Treatment A, Then C, Then B</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B3">
          <title>Treatment B, Then A, Then C</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B4">
          <title>Treatment B, Then C, Then A</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B5">
          <title>Treatment C, Then A, Then B</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B6">
          <title>Treatment C, Then B, Then A</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.
Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.
Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="9.2"/>
                    <measurement group_id="B2" value="23.4" spread="3.9"/>
                    <measurement group_id="B3" value="28.2" spread="8.2"/>
                    <measurement group_id="B4" value="30.3" spread="4.7"/>
                    <measurement group_id="B5" value="26.5" spread="7.4"/>
                    <measurement group_id="B6" value="24.8" spread="7.2"/>
                    <measurement group_id="B7" value="26.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose</title>
        <description>AUC(0-2hrs) (Area Under the Curve, time 0-2 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
        <time_frame>2 hours from time of first dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose</title>
          <description>AUC(0-2hrs) (Area Under the Curve, time 0-2 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>mmHg*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2794.93" spread="476.66"/>
                    <measurement group_id="O2" value="2580.06" spread="389.06"/>
                    <measurement group_id="O3" value="2497.71" spread="384.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With an Increase in PASP Greater Than 10mmHg From Baseline to 2 Hours From the First Dose</title>
        <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
        <time_frame>baseline and 2 hours from the time of first dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With an Increase in PASP Greater Than 10mmHg From Baseline to 2 Hours From the First Dose</title>
          <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change in PASP From Baseline to the Two Hour Period Following the First Dose</title>
        <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
        <time_frame>baseline and 2 hours from the time of first dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change in PASP From Baseline to the Two Hour Period Following the First Dose</title>
          <description>Pulmonary artery systolic pressure (PASP) is the highest pressure exerted on the walls of the pulmonary artery.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="4.4"/>
                    <measurement group_id="O2" value="19.2" spread="4.6"/>
                    <measurement group_id="O3" value="21.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max Change from Baseline over 2 hrs from 1st dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.4"/>
                    <measurement group_id="O2" value="6.1" spread="2.8"/>
                    <measurement group_id="O3" value="4.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-4hrs) of Pulmonary Arterial Systolic Pressure (PASP) From the Start of the First Dose to Two Hours After the Second Dose</title>
        <description>AUC(0-4hrs) (Area Under the Curve, time 0-4 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
        <time_frame>4 hours from the time of first dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose 2 hours from time of first dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-4hrs) of Pulmonary Arterial Systolic Pressure (PASP) From the Start of the First Dose to Two Hours After the Second Dose</title>
          <description>AUC(0-4hrs) (Area Under the Curve, time 0-4 hours post-1st dose) in PASP millimeters of mercury times minutes (mmHg*min). PASP is the highest pressure exerted on the walls of the pulmonary artery.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>mmHg*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5700.11" spread="1016.86"/>
                    <measurement group_id="O2" value="5336.38" spread="823.51"/>
                    <measurement group_id="O3" value="4907.03" spread="773.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure From Baseline After the Two 2-hour Post Dosing Periods</title>
        <description>Systolic and diastolic blood pressure measure the lowest and highest pressures against the walls of the arteries. Changes were calculated from 30 minutes pre dose (baseline) to 10 minutes post first and second dose. A positive change from baseline indicates an increase in blood pressure and a negative change indicates a decrease in blood pressure.</description>
        <time_frame>baseline, 10 minutes post 1st dose, 10 minutes post 2nd dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure From Baseline After the Two 2-hour Post Dosing Periods</title>
          <description>Systolic and diastolic blood pressure measure the lowest and highest pressures against the walls of the arteries. Changes were calculated from 30 minutes pre dose (baseline) to 10 minutes post first and second dose. A positive change from baseline indicates an increase in blood pressure and a negative change indicates a decrease in blood pressure.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" spread="11.3"/>
                    <measurement group_id="O2" value="113.3" spread="15.3"/>
                    <measurement group_id="O3" value="113.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 10 min in Systolic after 1st dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="10.0"/>
                    <measurement group_id="O2" value="4.7" spread="8.5"/>
                    <measurement group_id="O3" value="0.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 10 min in Systolic after 2nd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="7.8"/>
                    <measurement group_id="O2" value="1.2" spread="9.9"/>
                    <measurement group_id="O3" value="-0.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="7.3"/>
                    <measurement group_id="O2" value="67.2" spread="9.1"/>
                    <measurement group_id="O3" value="64.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 10 min in Diastolic after 1st dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.2"/>
                    <measurement group_id="O2" value="2.0" spread="8.0"/>
                    <measurement group_id="O3" value="1.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 10 min in Diastolic after 2nd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="11.2"/>
                    <measurement group_id="O2" value="-2.0" spread="9.4"/>
                    <measurement group_id="O3" value="0.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTc Interval at 14 Minutes After the 1st and 2nd Dose</title>
        <description>The corrected QT interval (QTc) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>baseline, 14 minutes from time of 1st dose, 14 minutes from time of 2nd dose</time_frame>
        <population>Patients with available data at the required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTc Interval at 14 Minutes After the 1st and 2nd Dose</title>
          <description>The corrected QT interval (QTc) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>Patients with available data at the required time point were included in the analysis population.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.9" spread="15.8"/>
                    <measurement group_id="O2" value="402.3" spread="19.0"/>
                    <measurement group_id="O3" value="399.9" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 14 mins post 1st dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="12.2"/>
                    <measurement group_id="O2" value="-0.8" spread="5.6"/>
                    <measurement group_id="O3" value="2.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 14 mins post 2nd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="10.7"/>
                    <measurement group_id="O2" value="-0.8" spread="13.4"/>
                    <measurement group_id="O3" value="4.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All subjects who were randomized and received at least one dose of study drug were included in the adverse event analysis. Adverse events are presented by treatment arm, not by individual treatment (intervention) received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensation of pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensory Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pharmaceutical product complaint</sub_title>
                <description>Medication Aftertaste</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>650-386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

